These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35191698)

  • 1. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.
    Qi J; Wang W; Tang Y; Lou S; Wang J; Yuan T; He Q; Yang B; Zhu H; Cui S
    J Med Chem; 2022 Mar; 65(5):3849-3865. PubMed ID: 35191698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
    Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
    J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
    Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
    Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
    Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
    Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
    Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
    J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
    Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
    Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
    Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
    J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
    Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Potent and Selective PI3Kδ Inhibitor (
    Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.
    Tang Y; Zheng F; Bao X; Zheng Y; Hu X; Lou S; Zhao H; Cui S
    J Med Chem; 2023 Sep; 66(17):11905-11926. PubMed ID: 37606563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.